NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 120
- Registration Number
- NCT00498303
- Locations
- 🇩🇪
Werksarztzentrum Herborn, Herborn, Germany
Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00494884
- Locations
- 🇩🇪
Novartis Investigative Site, Bochum, Germany
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 78
- Registration Number
- NCT00487825
- Locations
- 🇺🇸
Center for Arthritis and Rheumatic Diseases (Dr. Michael Weitz), South Miami, Florida, United States
🇺🇸Westroads Medical Group (Dr. William Palmer), Omaha, Nebraska, United States
🇺🇸West Broward Rheumatology Associates, Incorporated (Dr. Elias Halpert), Tamarac, Florida, United States
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 28
- Registration Number
- NCT00487058
Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- Novartis
- Registration Number
- NCT00487123
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2008-02-15
- Lead Sponsor
- Novartis
- Registration Number
- NCT00484003
- Locations
- 🇿🇦
Investigative Sites, Various Cities, South Africa
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00482248
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 95
- Registration Number
- NCT00482508
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 49
- Registration Number
- NCT00481676
- Locations
- 🇩🇪
Novartis Investigative Site, Munich, Germany
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 405
- Registration Number
- NCT00481065
© Copyright 2024. All Rights Reserved by MedPath